Publications

Burmester et al. provide insights into the benefit–risk profiles of UPA and adalimumab in patients with varying cardiovascular (CV) risks, suggesting that UPA may offer efficacy advantages over adalimumab irrespective of baseline CV risk, with generally similar rates of AEs. To better understand the benefits and risks of RA treatments in patients with different background CV risk, Burmester et al. assessed the short-term and long-term benefit–risk profiles of UPA and adalimumab in patients enrolled in SELECT-COMPARE.

Regardless of baseline CV risk, UPA demonstrated comparable safety to adalimumab, except for higher rates of HZ in both CV risk groups and NMSC and serious infections in the higher-risk group. The benefit–risk profile of UPA in RA patients was favourable, independent of CV risk category, in both short and long term.